Sign In
Buy CRIS
$0.500
-0.0025 (-0.498%)
At Close: Jun 03, 2026
Curis to Present at Upcoming Healthcare Conferences in April
07:30am, Thursday, 04'th Apr 2024
LEXINGTON, Mass. , April 4, 2024 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Curis, Inc. (NASDAQ: CRIS)
09:15am, Tuesday, 02'nd Apr 2024
NEW YORK , April 2, 2024 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Curis, Inc. (NASDAQ: CRIS) on behalf of the company's shareholders. The investigation seeks to det
Curis, Inc. (CRIS) Q4 2023 Earnings Call Transcript
02:04pm, Thursday, 08'th Feb 2024
Curis, Inc. (CRIS) Q4 2023 Earnings Call Transcript
Curis Provides Fourth Quarter 2023 Business Update
08:00am, Thursday, 08'th Feb 2024
Emavusertib data presented at ASH showed 3 of 5 patients achieved CR in R/R PCNSL Expansion of clinical sites in US and Europe in progress Cash runway into 2025 Management to host conference call toda
Curis to Release Fourth Quarter 2023 Financial Results and Hold Conference Call on February 8, 2024
08:00am, Thursday, 01'st Feb 2024
LEXINGTON, Mass. , Feb. 1, 2024 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhib
Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
08:00am, Friday, 05'th Jan 2024
LEXINGTON, Mass. , Jan. 5, 2024 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced t
Curis Announces Initial Combination Study Data from its TakeAim Lymphoma Study
08:00am, Tuesday, 12'th Dec 2023
LEXINGTON, Mass. , Dec. 12, 2023 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhi
Curis Presented Clinical Data from the TakeAim Leukemia Study at the 2023 ASH Conference
08:00am, Monday, 11'th Dec 2023
LEXINGTON, Mass. , Dec. 11, 2023 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inh
Curis Announces Three Presentations at ASH
08:00am, Wednesday, 06'th Dec 2023
LEXINGTON, Mass. , Dec. 6, 2023 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhib
Curis Enters into Agreement for Emavusertib / Pembrolizumab Combination Study in Melanoma
08:00am, Tuesday, 05'th Dec 2023
LEXINGTON, Mass. , Dec. 5, 2023 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhib
Curis's stock rises as analysts see ‘the next Pharmacyclics'
09:04am, Friday, 17'th Nov 2023
Shares of Curis Inc. CRIS, +4.23% gained nearly 6% premarket on Friday after Truist Securities analysts initiated coverage of the cancer-focused biotech company with a buy rating.
Curis, Inc. (CRIS) Q3 2023 Earnings Call Transcript
02:32pm, Thursday, 02'nd Nov 2023
Curis, Inc. (NASDAQ:CRIS ) Q3 2023 Earnings Conference Call November 2, 2023 8:30 AM ET Company Participants Diantha Duvall - Chief Financial Officer Jim Dentzer - President & Chief Executive Officer
Curis to Release Third Quarter 2023 Financial Results and Hold Conference Call on November 2, 2023
08:30am, Thursday, 26'th Oct 2023
LEXINGTON, Mass. , Oct. 26, 2023 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib, an orally available, small molecule IRAK4 inhibitor for
Curis to Present at Upcoming Healthcare Conferences in September
08:13am, Wednesday, 06'th Sep 2023
LEXINGTON, Mass. , Sept. 6, 2023 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib, an orally available small molecule IRAK4 inhibitor for t
Curis (CRIS) Reports Q2 Loss, Misses Revenue Estimates
07:32pm, Thursday, 03'rd Aug 2023
Curis (CRIS) came out with a quarterly loss of $0.12 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.17 per share a year ago.
